The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sorafenib monotherapy in patients with inoperable/recurrent germ cell tumors (GCT) refractory to chemotherapy: Phase II study.
Iwona Anna Skoneczna
Honoraria - Bayer
Research Funding - Bayer
Urszula Natorska
No relevant relationships to disclose
Malgorzata Tacikowska
No relevant relationships to disclose
Ewa Kraszewska
No relevant relationships to disclose
Beata Kotowicz
No relevant relationships to disclose
Malgorzata Fuksiewicz
No relevant relationships to disclose
Wojciech W Rogowski
No relevant relationships to disclose
Irena Federowicz
No relevant relationships to disclose
Grazyna Poniatowska
No relevant relationships to disclose
Agnieszka Chaladaj-Kujawska
No relevant relationships to disclose
Wojciech Michalski
No relevant relationships to disclose